RLAY

Relay Therapeutics, Inc. [RLAY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

RLAY Stock Summary

Top RLAY Correlated Resources

RLAY


Top 10 Correlated ETFs

RLAY


Top 10 Correlated Stocks

RLAY


In the News

08:21 04 Dec 2022 RLAY

Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

02:07 04 Dec 2022 RLAY

Relay Therapeutics: Best-In-Class Potential PIKCA Mutation Inhibitor

Relay Therapeutics' RLY-2608 is the first pan-allosteric PIKCA mutation inhibitor and has shown promise in preclinical studies, including better safety vs. Piqray (competition). Phase 1 dose escalation data for RLY-2608 is expected in the first half of 2023. The product candidate has the potential to be a blockbuster drug.

07:30 04 Dec 2022 RLAY

7 Unknown Biotech Stocks That Could Rocket in 2023

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

09:00 04 Dec 2022 RLAY

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Relay Therapeutics completed what was at the time the 3rd largest Biotech IPO in history in 2020, raising $400m. The company promised to use cutting edge AI driven technology to identify and develop drug targets with a primary focus on precision oncology.

10:39 04 Dec 2022 RLAY

Relay Therapeutics (NASDAQ:RLAY) – Why Relay Therapeutics Shares Are Getting Hammered

Relay Therapeutics Inc (NASDAQ: RLAY) shares are trading lower by 11.33% to $25.54 Tuesday morning after the company priced a roughly 11.32 million share public offering of common stock at $26.50 per share.

08:03 04 Dec 2022 RLAY

Relay Therapeutics (RLAY) Stock: Why It Fell Today

The stock price of Relay Therapeutics (RLAY) fell by 0.72% today. This is why.

04:05 04 Dec 2022 RLAY

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T. Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.

04:05 04 Dec 2022 RLAY

Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report second quarter 2022 financial results and corporate highlights after the close of market on Thursday, August 4, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release.

07:30 04 Dec 2022 RLAY

Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event

CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is open for the virtual analyst and investor event on June 27, 2022 from 8:00 a.m. to 9:00 a.m. ET.

07:30 04 Dec 2022 RLAY

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022, at 11:30 a.m. ET and at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 5:40 p.m. ET.

RLAY Financial details

Company Rating
Buy
Market Cap
2.27B
Income
-290.46M
Revenue
1.7M
Book val./share
9.01
Cash/share
9.5
Dividend
-
Dividend %
-
Employees
320
Optionable
No
Shortable
Yes
Earnings
22 Feb 2023
P/E
-4.88
Forward P/E
-7.32
PEG
-0.39
P/S
1228.14
P/B
2.08
P/C
1.93
P/FCF
-9.47
Quick Ratio
14.83
Current Ratio
15.22
Debt / Equity
0.05
LT Debt / Equity
0.05
-
-
EPS (TTM)
-2.77
EPS next Y
-2.51
EPS next Q
-0.5
EPS this Y
219.21%
EPS next Y
-9.49%
EPS next 5Y
-9.49%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-5.75%
EPS Q/Q
7.04%
-
-
-
-
SMA20
-18.18%
SMA50
-21.74%
SMA100
-10%
Inst Own
100%
Inst Trans
0%
ROA
-25%
ROE
-33%
ROC
-0.27%
Gross Margin
55%
Oper. Margin
-17354%
Profit Margin
-17136%
Payout
-
Shs Outstand
120.22M
Shs Float
79.62M
-
-
-
-
Target Price
23
52W Range
12.65-35.36
52W High
-47.53%
52W Low
+53.04%
RSI
38
Rel Volume
0.33
Avg Volume
1.22M
Volume
403.67K
Perf Week
-1.84%
Perf Month
-10.98%
Perf Quarter
32.41%
Perf Half Y
12.81%
-
-
-
-
Beta
1.02775
-
-
Volatility
0.32%, 1.47%
Prev Close
3.29%
Price
18.365
Change
-1%

RLAY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2020-12-31 2021-12-31
Revenue per share
1.940.07
Net income per share
-1.23-8.54
Operating cash flow per share
-2.4-1.75
Free cash flow per share
-2.45-1.83
Cash per share
15.9122.48
Book value per share
17.9121.07
Tangible book value per share
17.9121.01
Share holders equity per share
17.9121.07
Interest debt per share
00.54
Market cap
2.11B863.47M
Enterprise value
1.67B606.25M
P/E ratio
-40.32-2.37
Price to sales ratio
25.57285.07
POCF ratio
-20.62-11.6
PFCF ratio
-20.24-11.09
P/B Ratio
2.770.96
PTB ratio
2.770.96
EV to sales
20.15200.15
Enterprise value over EBITDA
-34.08-1.68
EV to operating cash flow
-16.25-8.15
EV to free cash flow
-15.95-7.78
Earnings yield
-0.02-0.42
Free cash flow yield
-0.05-0.09
Debt to equity
00.02
Debt to assets
0.050.11
Net debt to EBITDA
9.160.71
Current ratio
56.4940.14
Interest coverage
00
Income quality
1.960.2
Dividend Yield
00
Payout ratio
00
Sales general and administrative to revenue
0.4718.95
Research and developement to revenue
1.2157
Intangibles to total assets
00
Capex to operating cash flow
0.020.05
Capex to revenue
-0.02-1.15
Capex to depreciation
-0.54-0.88
Stock based compensation to revenue
0.3916
Graham number
22.2663.61
ROIC
-0.07-0.37
Return on tangible assets
-0.07-0.36
Graham Net
16.5119.97
Working capital
756.47M951.92M
Tangible asset value
0895.51M
Net current asset value
733.56M865.61M
Invested capital
00.03
Average receivables
82.65M43.8M
Average payables
6.35M7.31M
Average inventory
00
Days sales outstanding
365595.28
Days payables outstanding
00
Days of inventory on hand
00
Receivables turnover
10.61
Payables turnover
00
Inventory turnover
00
ROE
-0.07-0.41
Capex per share
-0.05-0.08

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.010.01000
Net income per share
-0.66-0.73-0.57-0.71-0.76
Operating cash flow per share
-0.57-0.43-0.45-0.53-0.6
Free cash flow per share
-0.59-0.44-0.48-0.54-0.62
Cash per share
6.6510.348.297.719.5
Book value per share
6.169.697.777.189.01
Tangible book value per share
6.169.667.777.158.99
Share holders equity per share
6.169.697.777.189.01
Interest debt per share
0.250.250.210.210.56
Market cap
2.92B2.85B3.24B1.82B2.48B
Enterprise value
2.72B2.59B3.14B1.73B2.19B
P/E ratio
-12.01-10.55-13.06-5.92-7.37
Price to sales ratio
4.39K5.02K7.74K4.99K7.21K
POCF ratio
-54.94-71.69-65.91-31.87-37.51
PFCF ratio
-53.2-70.14-62.37-30.87-36.36
P/B Ratio
5.123.173.852.332.48
PTB ratio
5.123.173.852.332.48
EV to sales
4.08K4.57K7.5K4.75K6.36K
Enterprise value over EBITDA
-45.42-38.98-52.08-23.17-27.91
EV to operating cash flow
-51.08-65.21-63.94-30.37-33.06
EV to free cash flow
-49.46-63.8-60.5-29.42-32.04
Earnings yield
-0.02-0.02-0.02-0.04-0.03
Free cash flow yield
-0.02-0.01-0.02-0.03-0.03
Debt to equity
0.040.020.020.030.05
Debt to assets
0.150.110.110.120.14
Net debt to EBITDA
3.433.871.611.153.76
Current ratio
22.4240.1421.9719.4915.22
Interest coverage
00-90.12-77.42-50.14
Income quality
0.870.590.790.740.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
22.0527.4238.3547.8546.73
Research and developement to revenue
67.5391.55123.31165.78194.48
Intangibles to total assets
00000
Capex to operating cash flow
0.030.020.060.030.03
Capex to revenue
-2.61-1.55-6.67-5.09-6.09
Capex to depreciation
-1.72-0.85-2.87-1.94-2.03
Stock based compensation to revenue
18.6518.0232.1141.539.88
Graham number
9.5412.5910.0110.6812.41
ROIC
-0.09-0.07-0.07-0.09-0.08
Return on tangible assets
-0.09-0.07-0.07-0.09-0.07
Graham Net
5.619.187.336.748.01
Working capital
610.74M951.92M874.1M811.89M1.02B
Tangible asset value
0895.51M0777.34M997.47M
Net current asset value
538.73M865.61M807.88M746.01M918.35M
Invested capital
0.040.030.030.030.06
Average receivables
5.05M5M5M5.05M5.08M
Average payables
5.31M6.29M6.17M4.3M6.89M
Average inventory
00000
Days sales outstanding
683.11784.131.06K1.25K1.34K
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.130.110.080.070.07
Payables turnover
00000
Inventory turnover
00000
ROE
-0.11-0.08-0.07-0.1-0.08
Capex per share
-0.02-0.01-0.03-0.02-0.02

RLAY Frequently Asked Questions

What is Relay Therapeutics, Inc. stock symbol ?

Relay Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol RLAY

Is Relay Therapeutics, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $23. The lowest prediction is $23 and the highest is $23

What is RLAY stock prediction ?

With a median analyst target price of $23, 1 stock analysts have made 1 forecasts in last 90 days. $23 is the lowest and $23 is the greatest projection.

What is Relay Therapeutics, Inc. stock quote today ?

Relay Therapeutics, Inc. stock price is $18.365 today.

Is Relay Therapeutics, Inc. stock public?

Yes, Relay Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap